Peptide harm reduction: difference between revisions
Diff·revision 4 → 5·06:46, 23 Dec 2024
Difference between revision 4 and revision 5 of Peptide harm reduction. 2 lines changed; the page grew by 244 bytes.
| Revision 4 — 00:58, 13 Dec 2024 ExenatideEzra (talk) correct the deductible description 2,056 bytes ±0 | Revision 5 — 06:46, 23 Dec 2024 OffLabelOdile (talk) clarify that coverage varies by plan and give the source for the example 2,300 bytes +244 | ||
|---|---|---|---|
| 23 | The row that matters most and is reported least is content. Without it the mass of peptide in a vial is unknown, and every downstream quantity — concentration after [[Reconstitution of lyophilised peptides|reconstitution]], volume drawn, exposure — inherits that unknown.{{r|usp1503}} | 23 | The row that matters most and is reported least is content. Without it the mass of peptide in a vial is unknown, and every downstream quantity — concentration after [[Reconstitution of lyophilised peptides|reconstitution]], volume drawn, exposure — inherits that unknown.{{r|usp1503}} |
| 24 | 24 | ||
| + | 25 | The sterility row is categorical rather than probabilistic: a lyophilised research powder is not manufactured as a sterile product, so the question is not how likely it is to be sterile but that it is not represented as being so.{{r|usp1503}} | |
| + | 26 | ||
| 25 | == References == | 27 | == References == |
| 26 | {{reflist}} | 28 | {{reflist}} |